Red Light Holland Corp. (CSE: TRIP) Reports Audited Financial Results, Details Strategic Evolution to Rhelion Life Sciences

2026-07-29, 5:54:32 a.m.

Toronto, Ontario — July 29, 2026 — Leads & Copy — Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF), an Ontario-based organization focused on innovation and research in the legal psychedelic sector, announced its audited annual consolidated financial statements and management’s discussion and analysis for the fiscal years ended March 31, 2026 and 2025. The company’s financial reports are available on its website and SEDAR+.

Following the acquisition of Filament Health Corp., Red Light Holland has enhanced its capabilities in pharmaceutical-grade manufacturing, regulatory affairs, and clinical research, including advancements in naturally derived psilocybin development and Filament’s botanical drug candidate, PEX010, in compliance with legal requirements. The company’s previously announced corporate rebrand to Rhelion Life Sciences Corp. is slated to take effect on August 4, 2026, signifying its transition to a science-first life sciences entity dedicated to the advancement of naturally derived psychedelic medicines. The company’s shares will continue trading under the existing tickers on their respective exchanges.

Fiscal 2026 was characterized by the strategic execution of a long-term vision, involving the simplification of legacy operations and the establishment of a vertically integrated platform focused on naturally derived psychedelic drug discovery, pharmaceutical manufacturing, intellectual property, and clinical development. The acquisition of Filament Health is considered foundational to this transformation, providing the company with a pharmaceutical platform encompassing proprietary intellectual property, GMP manufacturing capabilities, regulatory expertise, naturally derived drug candidates, and an international research network.

Key highlights of the integrated platform include 76 issued patents across 13 patent families, the proprietary botanical drug candidate PEX010, completed Phase I clinical development, and Phase II-ready development programs. The company also holds a Health Canada Level 8 Controlled Substances Dealer’s Licence and possesses GMP pharmaceutical-grade manufacturing infrastructure capable of producing botanical psilocybin capsules. This infrastructure supports over 80 clinical studies globally and includes FDA regulatory experience and international clinical development expertise. The company is also cultivating a network of pharmaceutical supply agreements, licensing opportunities, compassionate use programs, and academic collaborations across North America, Europe, and Oceania.

Management believes these combined capabilities position the company to contribute to the development of the regulated psychedelic medicine sector through an integrated platform. Throughout fiscal 2026, the company expanded its scientific and commercial reach through new research collaborations, pharmaceutical-grade supply agreements, and international partnerships. These initiatives involve continued support for clinical studies using Filament’s botanical drug candidates and preparations for additional Phase II clinical development for mental health and substance use disorders. The company is also strengthening its manufacturing capabilities and exploring future licensing opportunities.

Todd Shapiro, Chief Executive Officer and Director, stated that fiscal 2026 was focused on building a foundation for long-term value rather than maximizing short-term revenue. He highlighted the simplification of the operating portfolio, the exit from misaligned businesses, the strengthening of the balance sheet, and the concentration of capital on high-value opportunities. Shapiro emphasized that the Filament Health acquisition is a transformative event, creating a combined entity with significant intellectual property, GMP manufacturing, regulatory expertise, completed clinical development, and an expanding scientific network. He reiterated the mission to responsibly advance naturally derived psychedelic medicines through science, execution, and partnerships.

Key financial highlights for FY 2026 compared to FY 2025 include a decrease in total cash balance to $8.471 million from $12.838 million, a revenue decrease to $4.195 million from $4.944 million, and a gross profit decrease to $1.591 million from $1.913 million. General and administrative expenses also saw a slight decrease to $5.426 million from $5.686 million. The company reported an EBITDA loss of $6.754 million in FY 2026, an increase from $3.354 million in FY 2025, and an Adjusted EBITDA loss of $2.931 million, up from $2.532 million in FY 2025. Total assets decreased to $14.570 million as of March 31, 2026, from $21.221 million as of March 31, 2025.

In terms of legacy operations, Red Light Holland Netherlands completed the sale of SR Wholesale in June 2026 for €150,000, retaining certain iMicrodose brand rights and Wisdom Truffle inventory. The company is evaluating strategic alternatives for MiniChamp, including a potential sale. Happy Caps products remain available in over 250 retail stores seasonally, with plans to expand distribution. Shiitake mushroom production at AEM New Brunswick has been suspended since December 2025 due to industry challenges. Discussions are ongoing with a third party interested in acquiring the rights to the AEM Ontario farmland, plans, and permits, and the company has engaged a realtor to potentially sell the land, appraised at CAD$2 million.

Looking ahead, the company plans to focus on advancing its naturally derived drug development platform through continued investment in research, manufacturing, clinical development, and strategic partnerships. Key priorities for fiscal 2027 include advancing PEX010 and other drug candidates toward later-stage clinical development, expanding licensing and pharmaceutical-grade supply opportunities, leveraging its patent portfolio, expanding GMP manufacturing, optimizing non-core assets, and evaluating strategic acquisitions and partnerships. The company is actively exploring opportunities to advance PEX010 into a Phase 2b clinical program.

Management believes the psychedelic medicine sector is entering a period of increased regulatory acceptance and scientific validation, with naturally derived botanical medicines expected to play a significant role. The company’s drug development programs are subject to regulatory review and approval processes. Red Light Holland is a science and research-led company advancing natural psychedelic drug discovery and development, with its subsidiary Filament Health Corp. developing naturally derived psilocybin drug candidates.

Source: Red Light Holland Corp.

×

Welcome!

CannabisReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy

By Subscribing you will receive Daily Cannabis Story Leads via email 10:30 am ET Mon-Fri.